Risking Irrelevance in National Accounts
As managed care takes hold, corporate responses are being formulated at the top, leaving national account execs no longer in charge of formulating managed care strategy.
You may also be interested in...
After concerns from the medtech industry that a 2017 final rule requires sponsors with knowledge of off-label use of their product to add it to their label, the US FDA is proposing to delete the confusing text.
If President Donald Trump appoints, and the Senate approves, a new conservative justice for the Supreme Court to replace Ruth Bader Ginsburg, Affordable Care Act coverage could disappear. Two legal experts weigh in on this and other legal issues that could touch the medical device industry.
The Dutch start-up will use the funds to finalize product design for a neurostimulation platform targeting chronic migraines.